Wedbush Starts GTX Inc. (GTXI) at Outperform; Advanced Clinical Programs Are Underappreciated
Tweet
Share
E-mailGet Alerts GTXI Hot Sheet
Price: $1.20 --0%
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Wedbush initiates coverage on GTX Inc. (NASDAQ: GTXI) with an Outperform. PT $13.
Wedbush analyst says, "Ostarine, the company’s lead selective androgen receptor modulator (SARM) is entering Phase III trials to treat and prevent muscle wasting in non-small cell lung cancer (NSCLC) patients. Ostarine has demonstrated statistically significant increases in lean body mass (LBM) in cancer patients and also demonstrated clinical benefit in stair climb power...Top-line data from the Capesaris Phase IIb trial could read out in Q4:11; initial data from Ostarine’s Phase III program could read out in Q1:13."
For more ratings news on GTX Inc. click here and for the rating history of GTX Inc. click here.
Shares of GTX Inc. closed at $4.31 yesterday.
Wedbush analyst says, "Ostarine, the company’s lead selective androgen receptor modulator (SARM) is entering Phase III trials to treat and prevent muscle wasting in non-small cell lung cancer (NSCLC) patients. Ostarine has demonstrated statistically significant increases in lean body mass (LBM) in cancer patients and also demonstrated clinical benefit in stair climb power...Top-line data from the Capesaris Phase IIb trial could read out in Q4:11; initial data from Ostarine’s Phase III program could read out in Q1:13."
For more ratings news on GTX Inc. click here and for the rating history of GTX Inc. click here.
Shares of GTX Inc. closed at $4.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- Keefe, Bruyette & Woods Resumes Royal Bank of Canada (RY:CN) (RY) at Market Perform
- Truist Securities Starts Matthews International (MATW) at Hold, 'We see risk/reward as more balanced'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
